Drugs Made In America Acquisition II Corp. (DMII) Total Current Liabilities (2024 - 2026)

Drugs Made In America Acquisition (DMII) has reported Total Current Liabilities for 3 consecutive years, with $644574.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $644574.0 in Q2 2026; TTM through Jun 2026 was $644574.0, a N/A change from a year earlier, with the FY2025 full-year figure at $300864.0, up 18.09% from the prior year.
• Total Current Liabilities was $644574.0 for Q2 2026 at Drugs Made In America Acquisition, up from $300864.0 in the prior quarter.
• Over five years, Total Current Liabilities peaked at $677345.0 in Q3 2025 and troughed at $254783.0 in Q4 2024.
• A 3-year average of $469391.5 and a median of $472719.0 in 2025 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 18.09% in 2025, down 18.09% in 2025.
• Over 3 years, Total Current Liabilities stood at $254783.0 in 2024, then advanced by 18.09% to $300864.0 in 2025, then soared by 114.24% to $644574.0 in 2026.
• The last three Total Current Liabilities figures came in at $644574.0 (Q2 2026), $300864.0 (Q4 2025), and $677345.0 (Q3 2025), per Business Quant data.